ORal Antibiotics in Acute Mesenteric Ischemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

196 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-31

Study Completion Date

2027-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute mesenteric ischemia (AMI) is a life-threatening condition with an increasing incidence (7-13/100000 PY). The mortality of AMI is associated with the development and extent of transmural intestinal necrosis (IN), ranging from 25% without IN to 75% with IN. Given its potential reversibility, preventing the progression of AMI towards IN is now considered a primary therapeutic goal. Early management of AMI can thus avoid fatal outcomes and prevent lifelong complications such as short bowel syndrome. Following the results of a pilot study showing an improvement in survival and lower resection rates, our team created a first-of-its-kind intestinal stroke center (SURVI unit, Beaujon Hospital, Clichy, France) that provides 24/7 standardized multimodal and multidisciplinary care to AMI patients referred from all hospitals in the Paris region. As no randomized clinical trial has ever been conducted, the treatment offered by SURVI is based on pathophysiological knowledge and observational clinical data. AMI naturally progresses to sepsis, surgical complications, and multi-organ failure, direct consequences of IN. Features of sepsis are reported in up to 90% of AMI patients compared with 3-22% of patients with brain or myocardial ischemia, supporting a specific septic component in AMI. Experimental studies demonstrated reduced translocation and mortality in germ-free animals or after administration of oral antibiotics targeting Gram-negative and anaerobic early bacterial overgrowth and translocation. In a prospective observational study, the investigators recently suggested a protective effect of systematic oral antibiotics in terms of intestinal preservation, yielding a reduced occurrence of IN (HR: 0.16, 95% confidence interval 0.03-0.62). However, the systematic use of oral antibiotics in AMI remains controversial due to the individual and collective risk of increasing the carriage of multi-drug resistant bacterias.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

NCT05302531

Short Bowel Syndrome Infection, Bacterial

RECRUITING PHASE1

Performance of the SeptiCyte LAB Test for Antibiotic Stewardship in Mesenteric Ischemia

NCT06507423

Acute Mesenteric Ischemia Sepsis Bacterial Intra-abdominal Infection +1 more

COMPLETED

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

NCT06633718

Intra-abdominal Infections

NOT_YET_RECRUITING PHASE3

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

NCT00752219

Complicated Intra-abdominal Infections

COMPLETED PHASE2

Study of the Intestinal Microbiota

NCT07058961

Intestinal Microbiota Between Different Groups

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After the screening visit and informed consent collected by the recruiting investigator, all consecutive eligible patients (who will meet all inclusion criteria and none of exclusion criteria) will be included and randomized double-blind to oral antibiotics or double placebo group.

Patients will be evaluated at days 1, 3, 7, 14, 21 and 30 after the randomisation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Mesenteric Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

double-blind Gentamicin + Metronidazole versus placebo

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gentamicin + Metronidazole

Gentamicin 80 mg Metronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)

Group Type EXPERIMENTAL

Gentamicin

Intervention Type DRUG

Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)

Metronidazole

Intervention Type DRUG

Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)

Placebo

Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gentamicin

Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)

Intervention Type DRUG

Placebo

Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets

Intervention Type DRUG

Metronidazole

Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient aged 18 and less 90
* AMI of arterial occlusive origin, defined by the combination of

1. Onset \< 7 days of clinical, biological and/or radiological signs of acute intestinal injury in the territory of at least superior mesenteric ischemia, including right-side colitis,
2. significant vascular obstruction \> 75% of the superior mesenteric artery, and
3. no alternative diagnosis
* Admitted to the SURVI care network (Beaujon Hospital intensive care unit or SURVI, Bichat intensive care unit or vascular surgery department)

Exclusion Criteria

* Other forms of mesenteric ischemia (chronic without acute manifestations, venous, non-occlusive, strangulation, aortic dissection)
* Isolated left-side ischemic colitis
* Mesenteric vascular lesion without small bowel injury or right colon
* Not eligible for vascular or digestive surgery or intensive care (palliative context)
* Indication for an emergency surgical intestinal resection at the admission to the SURVI care network
* Indication for urgent systemic antibiotic treatment on admission (evidence of sepsis defined as a SOFA score of 2 or more associated with an infection)
* Systemic or oral antibiotic therapy within 7 days before inclusion
* Known hypersensitivity to the active substance /excipients
* Contraindications to the investigational medicinal products (gentamicin, metronidazole)
* Unable to give consent (under guardianship or curatorship)
* Subject deprived of freedom, subject under a legal protective measure
* Patient refusal to participate
* Non-affiliation to a social security regimen or CMU
* Patient under State Medical Aid
* Pregnant or breastfeeding women
* Participation in another clinical study involving investigational medicinal product or patient being in the exclusion period at the end of a previous study

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No